News | August 05, 2021
Alembic gets USFDA nod for Clomipramine Hydrochloride
It had an estimated market size of US $ 32 million as of June 2021
It had an estimated market size of US $ 32 million as of June 2021
It works as an adjunct to standard care based on robust clinical trials
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The group now has 320 approvals and has so far filed over 400 ANDAs
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated
